Rare form of eye stroke that causes blindness now linked to Ozempic and Wegovy.

- People taking Ozempic or Wegovy for diabetes or obesity may have a higher risk of developing a rare form of blindness called NAION - Study found that patients with diabetes were four times more likely and overweight or obese individuals were seven times more likely to experience NAION if taking semaglutide medications - Study published in JAMA Ophthalmology but cannot prove causal association between semaglutide medications and NAION - Novo Nordisk, manufacturer of semaglutide medications, emphasized that data in the study is not enough to establish a direct link - Experts recommend that potential risk of NAION should not deter the use of semaglutide medications to treat diabetes or obesity - FDA-approved labels for Ozempic and Wegovy include vision changes as potential side effects, ongoing studies to explore links between semaglutide use and eye issues - Patients on semaglutide or considering treatment should discuss risks and benefits with their doctors, especially if they have preexisting optic nerve problems

🚨 Reddit sentiment: mixed - Comments reflect concerns about study methodologies and possible risks but also highlight potential benefits, indicating an equal mix of caution and support for the stock linked to semaglutide use. Summarized comments: - Not controlled for BMI and diabetes? What kind of study is this - From a specialized medical center with a small patient number; risk remains uncommon and potential risk shouldn't deter use for treating diabetes or obesity - May make you blind but users joke about looking shredded - Confusing correlation with causation commented on - Taleb's Anti-fragile investment model referenced; downside risks of frequent pharmaceutical use versus potential benefits in life-threatening conditions - Obesity and related conditions complicate attributing the blindness condition to semaglutide without further studies; this minor issue versus drugs' life expectancy increase - Rare condition affecting up to 0.01%; obesity and diabetes are major heart disease contributors and people might take the risk - Commentary on societal reactions and biases toward weight loss via pharmaceuticals like semaglutide, highlighting serious risks of obesity itself Stock tickers discussed: $NVO